Semaglutide, 1.34 mg/mL + Empagliflozin 25 MG
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes With Renal Manifestations
Conditions
Type 2 Diabetes With Renal Manifestations
Trial Timeline
Nov 1, 2019 → Aug 1, 2021
NCT ID
NCT04061200About Semaglutide, 1.34 mg/mL + Empagliflozin 25 MG
Semaglutide, 1.34 mg/mL + Empagliflozin 25 MG is a approved stage product being developed by Novo Nordisk for Type 2 Diabetes With Renal Manifestations. The current trial status is unknown. This product is registered under clinical trial identifier NCT04061200. Target conditions include Type 2 Diabetes With Renal Manifestations.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04061200 | Approved | UNKNOWN |
Competing Products
20 competing products in Type 2 Diabetes With Renal Manifestations